Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Guerbet: Revenue at June 30, 2022
03:45pm, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
H1 2022 sales
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
12:00pm, Thursday, 14'th Jul 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in
The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations
12:00pm, Wednesday, 13'th Jul 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), has awarded grants of approxi
GBT Announces New Employment Inducement Grants
08:05pm, Thursday, 07'th Jul 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2022, the compensation committee of GBT’s boar
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2022
06:22am, Thursday, 07'th Jul 2022 GlobeNewswire Inc.
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2022
Global Blood (GBT) Initiates Phase II Study on SCD Candidate
03:47pm, Thursday, 30'th Jun 2022 Zacks Investment Research
Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the tr
Global Blood (GBT) Initiates Phase II Study on SCD Candidate
02:52pm, Thursday, 30'th Jun 2022
Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the tr
5 Top Biotech Stocks To Watch In July 2022
02:30pm, Thursday, 30'th Jun 2022
Amid choppy markets, could there be potential in these top biotech stocks?
Why Global Blood Therapeutics Trended Upward Today
07:27pm, Wednesday, 29'th Jun 2022 The Motley Fool
It started enrolling patients in a promising new clinical trial.
Why Global Blood Therapeutics Trended Upward Today
03:27pm, Wednesday, 29'th Jun 2022
It started enrolling patients in a promising new clinical trial.
Global Blood Therapeutics: Powerhouse Of The Future
06:31pm, Tuesday, 21'st Jun 2022
In the latest 1Q2022 earnings report, the lead medicine Oxbryta continues to generate highly aggressive growth. You can expect even stronger growth due to the recent Oxbryta launch for kids in the EU.
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mai 2022
02:02pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mai 2022
Guerbet reçoit l’approbation de l’EMA de son nom de marque Elucirem® pour Gadopiclenol
06:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Guerbet reçoit l’approbation de l’EMA de son nom de marque Elucirem® pour Gadopiclenol.
Guerbet erhält EMA-Zulassung für seinen Markennamen EluciremTM (Gadopiclenol)
06:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Guerbet erhält EMA-Zulassung für seinen Markennamen EluciremTM (Gadopiclenol)
Guerbet riceve dall'EMA l'approvazione del marchio EluciremTM per il Gadopiclenol
06:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Guerbet riceve dall'EMA l'approvazione del marchio EluciremTM per il Gadopiclenol.
